Interim results of a first-in-human phase 1 study of Q-1802, a CLDN18.2/PD-L1 bsABs, in patients with relapsed or refractory solid tumors - Yk, Wang; Gong, Jifang; Sun, Yuping; Zhang, Jian; Ni, Shuqin; Hou, Jie; Chen, Xiaohua; Wang, Yusheng; Yu, Qin; Qu, Xiangdong; Du, Yejie; Wei, Li; et al. (Journal of clinical oncology, 2023)